In its latest setback, Merck has announced ... in combination with Astellas/Pfizer’s Xtandi (enzalutamide) in metastatic castration-resistant prostate cancer (mCRPC) – its last remaining ...

A US district court has said that a key patent held by Astellas on its Myrbetriq drug for urinary incontinence is invalid, in a setback ... for Pfizer-partnered prostate cancer therapy Xtandi ...

The FDA has already approved PARP inhibitors in certain patients with metastatic castration-resistant prostate cancer (mCRPC) ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

We therefore did not pursue these models further. Fig 1. Predicted cumulative prostate cancer risks for a 45-year-old consultand by (A) father's age at prostate cancer diagnosis, (B) brother's age at ...

Story May 27 - Boundless Bio: After a phase 1/2 trial revealed shortcomings for Boundless’ lead cancer candidate ... that the biotech and partner Pfizer are dropping two phase 3 trials from ...

The latest news and headlines from Yahoo News. Get breaking news stories and in-depth coverage with videos and photos.

DiveWire guarantees visibility for your news announcements through instant distribution to MedTech Dive’s audience and its 60,000 newsletter subscribers for 21 days.